Plasmacytoid dendritic cells recruited by HIF-1α/eADO/ADORA1 signaling induce immunosuppression in hepatocellular carcinoma

Kulik, 2019, Epidemiology and management of hepatocellular carcinoma, Gastroenterology, 156, 477, 10.1053/j.gastro.2018.08.065 Forner, 2018, Hepatocellular carcinoma, Lancet, 391, 1301, 10.1016/S0140-6736(18)30010-2 Greten, 2018, Targets for immunotherapy of liver cancer, J. Hepatol., 68, 157, 10.1016/j.jhep.2017.09.007 Okusaka, 2018, Immunotherapy for hepatocellular carcinoma: current status and future perspectives, ESMO open, 3 Zheng, 2017, Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing, Cell, 169, 1342, 10.1016/j.cell.2017.05.035 Li, 2016, CXCL10/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation, J. Hepatol., 65, 944, 10.1016/j.jhep.2016.05.032 Shao, 2014, Regulatory B cells accelerate hepatocellular carcinoma progression via CD40/CD154 signaling pathway, Canc. Lett., 355, 264, 10.1016/j.canlet.2014.09.026 Yeung, 2015, Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma, J. Hepatol., 62, 607, 10.1016/j.jhep.2014.10.029 Zhou, 2018, Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy, Gut, 67, 931, 10.1136/gutjnl-2017-314032 Prieto, 2015, Immunological landscape and immunotherapy of hepatocellular carcinoma, Nat. Rev. Gastroenterol. Hepatol., 12, 681, 10.1038/nrgastro.2015.173 Zhou, 2019, Intratumoral plasmacytoid dendritic cells as a poor prognostic factor for hepatocellular carcinoma following curative resection, Canc. Immunol. Immunother., 68, 1223, 10.1007/s00262-019-02355-3 Pedroza-Gonzalez, 2015, Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors, OncoImmunology, 4, 10.1080/2162402X.2015.1008355 Sisirak, 2013, Plasmacytoid dendritic cells deficient in IFNα production promote the amplification of FOXP3+ regulatory T cells and are associated with poor prognosis in breast cancer patients, OncoImmunology, 2, 10.4161/onci.22338 Conrad, 2012, Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3+ T-regulatory cells, Canc. Res., 72, 5240, 10.1158/0008-5472.CAN-12-2271 Cella, 1999, Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon, Nat. Med., 5, 919, 10.1038/11360 Sisirak, 2012, Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression, Canc. Res., 72, 5188, 10.1158/0008-5472.CAN-11-3468 Swiecki, 2015, The multifaceted biology of plasmacytoid dendritic cells, Nat. Rev. Immunol., 15, 471, 10.1038/nri3865 Mitchell, 2018, Plasmacytoid dendritic cell in immunity and cancer, J. Neuroimmunol., 322, 63, 10.1016/j.jneuroim.2018.06.012 Yang, 2009, Hypoxia skews dendritic cells to a T helper type 2‐stimulating phenotype and promotes tumour cell migration by dendritic cell‐derived osteopontin, Immunology, 128, e237, 10.1111/j.1365-2567.2008.02954.x Kepp, 2017, Extracellular nucleosides and nucleotides as immunomodulators, Immunol. Rev., 280, 83, 10.1111/imr.12571 Seth, 2017, Deletion of lactate dehydrogenase-A in myeloid cells triggers antitumor immunity, Canc. Res., 77, 3632, 10.1158/0008-5472.CAN-16-2938 Boison, 2019, Adenosine metabolism: emerging concepts for cancer therapy, Canc. Cell, 36, 582, 10.1016/j.ccell.2019.10.007 Pang, 2018, ALEX1, a novel tumor suppressor gene, inhibits gastric cancer metastasis via the PAR-1/Rho GTPase signaling pathway, J. Gastroenterol., 53, 71, 10.1007/s00535-017-1329-y Grouard, 1997, The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand, J. Exp. Med., 185, 1101, 10.1084/jem.185.6.1101 Ling, 2014, Post-transplant endothelial progenitor cell mobilization via CXCL10/CXCR3 signaling promotes liver tumor growth, J. Hepatol., 60, 103, 10.1016/j.jhep.2013.08.017 Woo, 1994, Isolation, phenotype, and allostimulatory activity of mouse liver dendritic cells, Transplantation, 58, 484, 10.1097/00007890-199408270-00015 Kumar, 2014, Hypoxia‐inducible factors in regulation of immune responses in tumour microenvironment, Immunology, 143, 512, 10.1111/imm.12380 Chiu, 2017, Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma, Nat. Commun., 8, 1, 10.1038/s41467-017-00530-7 Murdoch, 2004, Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues, Blood, 104, 2224, 10.1182/blood-2004-03-1109 Nakano, 2001, CD11c+ B220+ Gr-1+ cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells, J. Exp. Med., 194, 1171, 10.1084/jem.194.8.1171 Colonna, 2004, Plasmacytoid dendritic cells in immunity, Nat. Immunol., 5, 1219, 10.1038/ni1141 Schnurr, 2004, Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells, Blood, 103, 1391, 10.1182/blood-2003-06-1959 Vijayan, 2017, Targeting immunosuppressive adenosine in cancer, Nat. Rev. Canc., 17, 709, 10.1038/nrc.2017.86 Stagg, 2010, Extracellular adenosine triphosphate and adenosine in cancer, Oncogene, 29, 5346, 10.1038/onc.2010.292 Antonioli, 2013, CD39 and CD73 in immunity and inflammation, Trends Mol. Med., 19, 355, 10.1016/j.molmed.2013.03.005 Leone, 2018, Targeting adenosine for cancer immunotherapy, J. Immunother. Canc., 6, 57, 10.1186/s40425-018-0360-8 Ohta, 2016, A metabolic immune checkpoint: adenosine in tumor microenvironment, Front. Immunol., 7, 109, 10.3389/fimmu.2016.00109 Ray, 2015, Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells, Leukemia, 29, 1441, 10.1038/leu.2015.11 Barsoum, 2014, Mechanisms of hypoxia-mediated immune escape in cancer, Canc. Res., 74, 7185, 10.1158/0008-5472.CAN-14-2598 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Zou, 2001, Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells, Nat. Med., 7, 1339, 10.1038/nm1201-1339 Vermi, 2003, Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas, J. Pathol., 200, 255, 10.1002/path.1344 Sharma, 2007, Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2, 3-dioxygenase, J. Clin. Invest., 117, 2570, 10.1172/JCI31911 Munn, 2004, Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes, J. Clin. Invest., 114, 280, 10.1172/JCI21583 Beaudoin, 2014, Plasmacytoid dendritic cells license regulatory T cells, upon iNKT‐cell stimulation, to prevent autoimmune diabetes, Eur. J. Immunol., 44, 1454, 10.1002/eji.201343910 Bogdan, 2015, Nitric oxide synthase in innate and adaptive immunity: an update, Trends Immunol., 36, 161, 10.1016/j.it.2015.01.003 Le Mercier, 2013, Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment, Canc. Res., 73, 4629, 10.1158/0008-5472.CAN-12-3058 Nierkens, 2011, Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells, Canc. Res., 71, 6428, 10.1158/0008-5472.CAN-11-2154 Gil, 2014, CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells, J. Immunol., 193, 5327, 10.4049/jimmunol.1400201 Allard, 2013, Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs, Clin. Canc. Res., 19, 5626, 10.1158/1078-0432.CCR-13-0545 Li, 2019, Targeting CD39 in cancer reveals an extracellular ATP- and inflammasome-driven tumor immunity, Canc. Discov., 9, 1754, 10.1158/2159-8290.CD-19-0541